Heterologous Gam-COVID-Vac (Sputnik V)/mRNA-1273 (Moderna) vaccination: Author's response

Pereson, Matías J.; Neukam, Karin; Amaya, Lucas; Baré, Patricia; Echegoyen, Natalia; Badano, María Noel; Lucero, Alicia; Martelli, Antonella; García, Gabriel; Videla, Cristina; Martínez, Alfredo P.; Lello, Federico A. Di

doi:10.1016/j.cmi.2022.06.007

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead, government-imposed lockdowns and social distancing were utilized as preventative measures (4), but due to high transmissibility and virulence the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for nearly 400 coronavirus disease-19 (COVID-19) related medical products in the United States, including diagnostic tests, medical devices, drugs, and vaccines (4,(6)(7)(8), and helped distribute vaccines worldwide. Prior work has shown that post-vaccine immunity is driven by various factors, including prior SARS-CoV-2 infection, vaccine manufacturer, heterologous booster administration, time since vaccination, and the magnitude of peak antibody titers after vaccination (9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Furthermore, both systemic and local symptoms following SARS-CoV-2 infection and vaccination have been associated with higher peak antibody responses following primary vaccination (5).…”

Section: Introductionmentioning

confidence: 99%

Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort

Tribin,

Williams,

Testamarck

et al. 2023

Preprint

View full text Add to dashboard Cite

Post vaccine immunity following COVID-19 mRNA vaccination may be driven by extrinsic, or controllable and intrinsic, or inherent health factors. Thus, we investigated the effects of extrinsic and intrinsic on the peak antibody response following COVID-19 primary vaccination and on the trajectory of peak antibody magnitude and durability over time. Participants in a longitudinal cohort attended visits every 3 months for up to 2 years following enrollment. At baseline, participants provided information on their demographics, recreational behaviors, and comorbid health conditions which guided our model selection process. Blood samples were collected for serum processing and spike antibody testing at each visit. Cross-sectional and longitudinal models (linear-mixed effects models) were generated to assess the relationship between selected intrinsic and extrinsic health factors on peak antibody following vaccination and to determine the influence of these predictors on antibody over time. Following cross-sectional analysis, we observed higher peak antibody titers after primary vaccination in females, those who reported recreational drug use, younger age, and prior COVID-19 history. Following booster vaccination, females and Hispanics had higher peak titers after the 3rdand 4thdoses, respectively. Longitudinal models demonstrated that Moderna mRNA-1273 recipients, females, and those previously vaccinated had increased peak titers over time. Moreover, drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers over time following the first booster, while no predictive factors significantly affected post-second booster antibody responses. Overall, both intrinsic and extrinsic health factors play a significant role in shaping humoral immunogenicity after initial vaccination and the first booster. The absence of predictive factors for second booster immunogenicity suggests a more robust and consistent immune response after the second booster vaccine administration.

show abstract